MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.31
+0.11
+0.54%
Closed 18:35 09/25 EDT
OPEN
20.15
PREV CLOSE
20.20
HIGH
20.55
LOW
20.00
VOLUME
336.74K
TURNOVER
--
52 WEEK HIGH
29.36
52 WEEK LOW
13.12
MARKET CAP
1.07B
P/E (TTM)
9.22
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Supernus' Value Proposition Has Improved With Recent Sell-Off
Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow. Despite this, Supernus' stock has dropped off substantially of late. I still view Supernus as a strong value play at present.
Seekingalpha · 3h ago
Supernus Pharmaceuticals (SUPN) Investor Presentation - Slideshow
The following slide deck was published by Supernus Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 09/17 23:20
Top Pharmaceutical Stocks for Q4 2020
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
Investopedia · 09/15 18:11
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinsons Disease Who Have Failed Two Treatments
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Application (NDA)
GlobeNewswire · 09/14 13:15
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview
GlobeNewswire · 09/09 21:30
Supernus to Present at the Wells Fargo Virtual Health Care Conference
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview
GlobeNewswire · 09/02 21:30
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2020 Earnings Conference Call August 19, 2020 09:00 AM ET Company Participants Peter Vozzo - IR, Westwicke Jack Khattar - President and CEO Greg Patrick - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler David Steinberg - Jefferies Annabel Samimy - Stifel Nicolaus Presentation Operator Good morning, and welcome to the Supernus Pharmaceuticals Second Quarter 2020 Financial Results Conference Call.
Seeking Alpha - Transcript · 08/19 17:54
More on Supernus Pharmaceutical Q2 earnings
For Q2, Supernus Pharmaceuticals ([[SUPN]] -4.6%) reported revenue of $126.73M (+21.0% Y/Y) missed consensus by $5.27M.GAAP EPS of $0.65 (vs. $0.61 in year ago quarter) beats consensus by $0.16.As of June 30,
Seekingalpha · 08/19 15:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SUPN. Analyze the recent business situations of Supernus Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SUPN stock price target is 28.75 with a high estimate of 35.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 367
Institutional Holdings: 60.20M
% Owned: 114.30%
Shares Outstanding: 52.66M
TypeInstitutionsShares
Increased
80
4.77M
New
68
-65.56K
Decreased
66
3.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Charles Newhall
President/Chief Executive Officer/Secretary/Director
Jack Khattar
Chief Financial Officer/Senior Vice President/IR Contact Officer
Gregory Patrick
Executive Vice President
Stefan Schwabe
Senior Vice President/Chief Scientific Officer
Padmanabh Bhatt
Senior Vice President
Tami Martin
Senior Vice President
Frank Mottola
Independent Director
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Frederick Hudson
Independent Director
John Siebert
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SUPN
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.